Free Trial
→ Your temporary download link is expiring (From Profits Run) (Ad)tc pixel Free EWTX Stock Alerts

Edgewise Therapeutics (EWTX) Financials

Edgewise Therapeutics logo
$33.76 -0.25 (-0.74%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$33.80 +0.04 (+0.10%)
As of 05:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Edgewise Therapeutics

Annual Income Statements for Edgewise Therapeutics

This table shows Edgewise Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -43 -68 -99 -133 -168
Consolidated Net Income / (Loss)		 -17 -43 -68 -100 -134 -168
Net Income / (Loss) Continuing Operations		 -17 -43 -68 -100 -134 -168
Total Pre-Tax Income 		-17 -43 -68 -100 -134 -168
Total Operating Income		 -17 -43 -72 -114 -159 -191
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 43 72 114 159 191
Selling, General & Admin Expense		 2.21 11 18 23 32 40
Research & Development Expense		 15 32 54 91 127 151
Total Other Income / (Expense), net		 0.07 0.40 4.02 14 25 24
Interest & Investment Income		 0.07 0.40 4.02 14 25 24
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - -1.45 -0.32 -0.26
Basic Earnings per Share		 - - - ($1.57) ($1.45) ($1.63)
Weighted Average Basic Shares Outstanding		 739.00K 37.53M 53.59M 63.72M 92.41M 102.93M
Diluted Earnings per Share		 - - - ($1.57) ($1.45) ($1.63)
Weighted Average Diluted Shares Outstanding		 739.00K 37.53M 53.59M 63.72M 92.41M 102.93M
Weighted Average Basic & Diluted Shares Outstanding		 - 49.51M 63.26M 93.11M 95.21M 107.27M

Quarterly Income Statements for Edgewise Therapeutics

This table shows Edgewise Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -26 -30 -29 -31 -34 -42 -41 -36 -41 -50 -50
Consolidated Net Income / (Loss)		 -26 -30 -29 -31 -34 -40 -41 -36 -41 -50 -49
Net Income / (Loss) Continuing Operations		 -26 -30 -29 -31 -34 -40 -41 -36 -41 -50 -49
Total Pre-Tax Income 		-26 -30 -29 -31 -34 -40 -41 -36 -41 -50 -49
Total Operating Income		 -29 -34 -35 -38 -40 -46 -46 -43 -47 -56 -54
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 29 34 35 38 40 46 46 43 47 56 54
Selling, General & Admin Expense		 5.67 6.18 7.06 7.43 8.21 9.17 9.20 9.05 9.38 12 11
Research & Development Expense		 24 28 28 31 32 36 37 34 37 44 43
Total Other Income / (Expense), net		 3.74 3.72 6.23 6.61 6.30 5.88 5.16 6.50 6.19 5.76 5.10
Interest & Investment Income		 3.74 3.72 6.23 6.61 6.30 5.88 5.16 6.50 6.19 5.76 5.10
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - 0.02 - - - 0.93
Basic Earnings per Share		 - - - - - - ($0.43) - - - ($0.46)
Weighted Average Basic Shares Outstanding		 63.46M 63.72M 87.57M 93.52M 93.81M 92.41M 95.13M 104.94M 105.49M 102.93M 107.12M
Diluted Earnings per Share		 - - - - - - ($0.43) - - - ($0.46)
Weighted Average Diluted Shares Outstanding		 63.46M 63.72M 87.57M 93.52M 93.81M 92.41M 95.13M 104.94M 105.49M 102.93M 107.12M
Weighted Average Basic & Diluted Shares Outstanding		 63.46M 93.11M 93.40M 93.77M 94.69M 95.21M 105.20M 105.35M 105.87M 107.27M 107.59M

Annual Cash Flow Statements for Edgewise Therapeutics

This table details how cash moves in and out of Edgewise Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 81 -89 6.43 64 -44 19
Net Cash From Operating Activities		 -15 -34 -53 -92 -109 -144
Net Cash From Continuing Operating Activities		 -15 -34 -53 -92 -109 -144
Net Income / (Loss) Continuing Operations		 -17 -43 -68 -100 -134 -168
Consolidated Net Income / (Loss)		 -17 -43 -68 -100 -134 -168
Depreciation Expense		 0.19 0.27 0.37 1.55 2.07 2.08
Amortization Expense		 - 0.00 -0.37 -9.34 -12 -7.48
Non-Cash Adjustments To Reconcile Net Income		 0.35 4.40 11 18 25 34
Changes in Operating Assets and Liabilities, net		 1.95 4.63 4.09 -1.56 10 -4.63
Net Cash From Investing Activities		 -24 -242 -71 103 -185 -33
Net Cash From Continuing Investing Activities		 -24 -242 -71 103 -185 -33
Purchase of Property, Plant & Equipment		 -0.20 -0.67 -5.55 -5.75 -1.31 -0.26
Purchase of Investments		 -24 -288 -292 -256 -477 -527
Sale and/or Maturity of Investments		 0.00 47 227 364 294 495
Net Cash From Financing Activities		 120 186 130 53 249 196
Net Cash From Continuing Financing Activities		 120 186 130 53 249 196
Repayment of Debt		 - 0.00 -0.25 -0.17 -0.26 0.00
Issuance of Common Equity		 0.00 186 129 53 240 188
Other Financing Activities, net		 0.20 0.11 0.41 0.12 9.48 7.80

Quarterly Cash Flow Statements for Edgewise Therapeutics

This table details how cash moves in and out of Edgewise Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 1.15 53 -56 13 1.32 -3.14 8.26 -6.52 2.60 15 -28
Net Cash From Operating Activities		 -22 -27 -29 -26 -27 -27 -38 -33 -35 -39 -43
Net Cash From Continuing Operating Activities		 -22 -27 -29 -26 -27 -27 -38 -33 -35 -39 -43
Net Income / (Loss) Continuing Operations		 -26 -30 -29 -31 -34 -40 -41 -36 -41 -50 -49
Consolidated Net Income / (Loss)		 -26 -30 -29 -31 -34 -40 -41 -36 -41 -50 -49
Depreciation Expense		 0.45 0.48 0.47 0.48 0.54 0.58 0.51 0.52 0.52 0.53 0.54
Amortization Expense		 -2.33 -2.12 -3.10 -3.50 -3.18 -2.55 -1.88 -2.16 -2.01 -1.43 -0.96
Non-Cash Adjustments To Reconcile Net Income		 4.57 5.14 4.71 5.39 6.37 8.25 9.06 7.55 8.45 9.13 8.72
Changes in Operating Assets and Liabilities, net		 0.96 -0.19 -2.16 3.03 3.03 6.43 -4.76 -2.38 -1.08 3.41 -1.82
Net Cash From Investing Activities		 23 27 -268 37 25 21 44 -162 36 50 2.43
Net Cash From Continuing Investing Activities		 23 27 -268 37 25 21 44 -162 36 50 2.43
Purchase of Property, Plant & Equipment		 -0.46 -0.16 -0.14 -0.22 0.31 -1.11 -0.04 -0.08 -0.11 -0.07 -0.26
Purchase of Investments		 -85 -40 -328 -41 -45 -63 -122 -264 -67 -74 -110
Sale and/or Maturity of Investments		 109 67 60 79 71 84 166 102 103 124 113
Net Cash From Financing Activities		 -0.21 53 241 1.95 3.33 2.90 2.22 188 1.66 3.98 12
Net Cash From Continuing Financing Activities		 -0.21 53 241 1.95 3.33 2.90 2.22 188 1.66 3.98 12
Repayment of Debt		 -0.21 0.05 0.00 - -0.21 - -0.04 0.04 - - 0.00
Issuance of Common Equity		 - 53 239 0.42 - 0.47 0.00 188 - 0.33 0.00
Other Financing Activities, net		 0.00 0.06 1.93 1.58 3.55 2.43 2.26 0.23 1.66 3.65 12

Annual Balance Sheets for Edgewise Therapeutics

This table presents Edgewise Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 131 285 367 340 487 553
Total Current Assets		 130 284 357 327 475 543
Cash & Equivalents		 105 16 22 86 42 61
Short-Term Investments		 24 265 330 232 429 469
Prepaid Expenses		 0.55 2.98 5.05 8.60 5.31 13
Plant, Property, & Equipment, net		 0.52 0.91 8.53 10 9.50 7.83
Total Noncurrent Assets		 0.98 0.55 1.57 2.60 1.83 1.39
Other Noncurrent Operating Assets		 0.98 0.00 1.57 2.60 1.83 1.39
Total Liabilities & Shareholders' Equity		 131 285 367 340 487 553
Total Liabilities		 4.34 11 20 21 28 30
Total Current Liabilities		 4.34 11 17 17 24 27
Accounts Payable		 1.58 3.84 6.11 4.03 5.58 6.01
Accrued Expenses		 1.59 3.88 5.84 6.07 7.23 7.92
Current Employee Benefit Liabilities		 1.18 2.80 4.03 5.70 10 12
Other Current Liabilities		 - 0.00 0.61 0.98 1.00 1.01
Total Noncurrent Liabilities		 0.00 0.33 3.80 4.43 3.74 2.98
Other Noncurrent Operating Liabilities		 0.00 0.33 3.80 4.43 3.74 2.98
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -33 274 347 319 459 522
Total Preferred & Common Equity		 -33 274 347 319 459 522
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -33 274 347 319 459 522
Common Stock		 0.73 352 493 563 837 1,068
Retained Earnings		 -34 -77 -145 -245 -379 -546
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.51 -1.36 0.10 0.42 0.68

Quarterly Balance Sheets for Edgewise Therapeutics

This table presents Edgewise Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 346 331 311 554 532 511 454 613 583 519
Total Current Assets		 333 317 298 541 519 499 443 603 574 510
Cash & Equivalents		 48 32 33 30 43 45 50 43 46 33
Short-Term Investments		 280 278 257 502 468 448 386 551 517 466
Prepaid Expenses		 5.41 7.07 8.22 8.67 7.69 6.90 6.79 9.26 11 10
Plant, Property, & Equipment, net		 10 11 11 10 9.90 9.97 8.99 8.60 8.13 7.40
Total Noncurrent Assets		 2.64 2.77 2.76 2.20 2.31 1.88 2.22 1.48 1.44 1.33
Other Noncurrent Operating Assets		 2.64 2.77 2.76 2.20 2.31 1.88 2.22 1.48 1.44 1.33
Total Liabilities & Shareholders' Equity		 346 331 311 554 532 511 454 613 583 519
Total Liabilities		 18 19 21 19 21 22 25 24 25 25
Total Current Liabilities		 13 14 16 15 17 19 21 21 22 23
Accounts Payable		 3.88 3.78 5.32 4.72 6.80 5.65 8.79 8.32 6.16 7.29
Accrued Expenses		 5.97 6.62 5.68 5.97 5.14 6.13 7.35 5.94 6.48 8.56
Current Employee Benefit Liabilities		 2.07 3.13 4.41 2.92 4.24 6.19 3.97 5.64 8.00 5.68
Other Current Liabilities		 0.80 0.87 0.93 0.98 0.99 0.99 1.00 1.00 1.01 1.02
Total Noncurrent Liabilities		 4.85 4.77 4.60 4.27 4.00 3.45 3.56 3.37 3.17 2.78
Other Noncurrent Operating Liabilities		 4.85 4.77 4.60 4.27 4.00 3.45 3.56 3.37 3.17 2.78
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 329 311 290 535 510 489 430 589 559 493
Total Preferred & Common Equity		 329 311 290 535 510 489 430 589 559 493
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 329 311 290 535 510 489 430 589 559 493
Common Stock		 497 501 505 809 816 827 849 1,044 1,054 1,089
Retained Earnings		 -167 -189 -215 -273 -305 -339 -419 -455 -496 -595
Accumulated Other Comprehensive Income / (Loss)		 -0.25 -0.55 -0.42 -0.86 -1.05 1.05 0.40 0.20 0.70 -0.25

Annual Metrics And Ratios for Edgewise Therapeutics

This table displays calculated financial ratios and metrics derived from Edgewise Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -152.50% -66.88% -70.44% -38.43% -16.39%
EBIT Growth		 0.00% -151.37% -65.82% -59.59% -38.89% -20.51%
NOPAT Growth		 0.00% -151.37% -65.82% -59.59% -38.89% -20.51%
Net Income Growth		 0.00% -150.03% -57.99% -48.08% -33.60% -25.40%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -12.41%
Operating Cash Flow Growth		 0.00% -128.97% -57.09% -74.69% -18.58% -31.91%
Free Cash Flow Firm Growth		 0.00% 0.00% -102.70% -65.21% -16.42% -37.37%
Invested Capital Growth		 0.00% -202.35% 24.78% 108.35% -2,606.64% 28.32%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -30.72% 0.00% -10.65% -7.65% -5.00%
EBIT Q/Q Growth		 0.00% -30.58% 0.00% -11.49% -7.94% -5.77%
NOPAT Q/Q Growth		 0.00% -30.58% 0.00% -11.49% -7.94% -5.77%
Net Income Q/Q Growth		 0.00% -17.43% 0.00% -12.00% -7.66% -6.71%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% -16.64% 0.00% -19.45% -0.12% -8.80%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -920.33% -18.18% -1.19% -9.11%
Invested Capital Q/Q Growth		 0.00% -36.76% 0.00% -40.14% -199.37% -67.31%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.60% 99.07% 94.39% 87.59% 84.25% 87.66%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -13.50% -21.34% -21.78% -30.10% -34.40% -34.19%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -19,615.08% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 3.56% -12.82% -21.78% -30.10% -34.40% -34.19%
Return on Equity Simple (ROE_SIMPLE)		 51.24% -15.60% -19.51% -31.42% -29.14% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -30 -50 -80 -111 -134
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.94% -6.12% -5.52% -6.00% -5.74% -6.76%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -25.11% -24.21% -25.65%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -17 -43 -72 -114 -159 -191
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -43 -72 -122 -169 -197
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.75 1.28 2.18 5.51 5.03
Price to Tangible Book Value (P/TBV)		 0.00 2.75 1.28 2.18 5.51 5.03
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 860.13 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.02 -1.01 -1.01 -1.02
Leverage Ratio		 1.03 1.04 1.05 1.06 1.06 1.06
Compound Leverage Factor		 1.03 1.03 0.99 0.93 0.90 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 126.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -26.36% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 24.67 41.93 13.02 18.62 53.91 50.54
Noncontrolling Interest Sharing Ratio		 126.36% 39.94% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 29.86 26.97 21.53 19.50 19.93 19.85
Quick Ratio		 29.73 26.69 21.22 18.98 19.71 19.37
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -26 -52 -86 -100 -137
Operating Cash Flow to CapEx		 -7,208.87% -5,016.02% -949.06% -1,600.49% -8,310.06% -56,178.13%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -2.30 -6.95 -5.23 0.44 -11 -7.85
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -4.65 1.72 5.67 -11 3.10
Enterprise Value (EV)		 207 472 93 376 2,058 2,097
Market Capitalization		 176 753 445 694 2,528 2,627
Book Value per Share		 ($45.22) $5.57 $6.47 $5.02 $4.85 $4.93
Tangible Book Value per Share		 ($45.22) $5.57 $6.47 $5.02 $4.85 $4.93
Total Capital		 127 274 347 319 459 522
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -129 -281 -352 -318 -470 -530
Capital Expenditures (CapEx)		 0.20 0.67 5.55 5.75 1.31 0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.79 -7.54 -12 -8.17 -19 -14
Debt-free Net Working Capital (DFNWC)		 125 273 340 310 452 516
Net Working Capital (NWC)		 125 273 340 310 452 516
Net Nonoperating Expense (NNE)		 5.09 13 17 20 23 34
Net Nonoperating Obligations (NNO)		 -129 -281 -352 -318 -470 -530
Total Depreciation and Amortization (D&A)		 0.19 0.27 -0.01 -7.79 -10 -5.40
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.63)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 37.53M 53.59M 63.72M 92.41M 102.93M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.63)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 37.53M 53.59M 63.72M 92.41M 102.93M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 49.51M 63.26M 93.11M 95.21M 107.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -30 -50 -80 -111 -134
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.29% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Edgewise Therapeutics

This table displays calculated financial ratios and metrics derived from Edgewise Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 107,270,521.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 107,270,521.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.47
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -74.35% -49.53% -35.73% -48.08% -37.47% -33.84% -26.62% -7.59% -12.25% -19.73% -15.23%
EBIT Growth		 -61.27% -53.37% -35.20% -50.39% -37.28% -34.49% -32.24% -11.82% -15.89% -22.92% -17.75%
NOPAT Growth		 -61.27% -53.37% -35.20% -50.39% -37.28% -34.49% -32.24% -11.82% -15.89% -22.92% -17.75%
Net Income Growth		 -46.95% -55.26% -24.90% -46.71% -32.73% -31.58% -43.03% -14.66% -19.15% -26.61% -20.14%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.98%
Operating Cash Flow Growth		 -84.39% -126.32% -25.29% -28.99% -24.10% -0.47% -32.41% -24.84% -27.04% -43.16% -12.35%
Free Cash Flow Firm Growth		 -19.46% -70.98% -5.19% -12.05% -12.03% 30.25% 8.98% -9.69% -32.84% -106.41% -63.75%
Invested Capital Growth		 0.00% 108.35% 145.72% -183.63% -601.23% -2,606.64% -405.59% -285.36% -28.26% 28.32% 4.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.81% -13.31% -5.29% -10.03% -4.73% -10.32% 0.39% 6.51% -9.26% -17.67% 4.13%
EBIT Q/Q Growth		 -16.23% -14.97% -2.63% -9.65% -6.10% -12.63% -0.92% 7.29% -9.97% -19.47% 3.33%
NOPAT Q/Q Growth		 -16.23% -14.97% -2.63% -9.65% -6.10% -12.63% -0.92% 7.29% -9.97% -19.47% 3.33%
Net Income Q/Q Growth		 -19.77% -17.23% 5.37% -10.42% -8.36% -16.21% -2.86% 11.48% -12.60% -23.48% 2.40%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -9.01% -21.63% -6.59% 8.74% -4.89% 1.52% -40.47% 13.95% -6.73% -10.97% -10.24%
Free Cash Flow Firm Q/Q Growth		 -0.20% -37.59% 12.77% 6.83% -0.18% 14.33% -13.83% -12.27% -21.33% -33.12% 9.69%
Invested Capital Q/Q Growth		 -52.19% -40.14% 399.31% -158.52% -186.53% -199.37% 39.13% 26.20% 4.63% -67.31% 19.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 87.30% 89.02% 82.08% 82.65% 84.41% 87.09% 88.77% 84.76% 86.79% 89.71% 90.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -61.59% -30.10% -24.51% -28.20% -31.90% -34.40% -30.29% -27.41% -30.02% -34.19% -38.14%
Cash Return on Invested Capital (CROIC)		 -19,871.73% -19,615.08% -5,711.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -61.59% -30.10% -24.51% -28.20% -31.90% -34.40% -30.29% -27.41% -30.02% -34.19% -38.14%
Return on Equity Simple (ROE_SIMPLE)		 -30.79% 0.00% -19.79% -22.70% -25.42% 0.00% -34.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -24 -24 -27 -28 -32 -32 -30 -33 -39 -38
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.52% -1.92% -0.98% -1.17% -1.49% -1.97% -1.78% -1.14% -1.49% -2.21% -2.38%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.43% - - - -6.94% -7.49% -5.06% -5.87% -7.50% -7.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -29 -34 -35 -38 -40 -46 -46 -43 -47 -56 -54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -36 -37 -41 -43 -48 -47 -44 -48 -57 -55
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.25 2.18 2.16 3.30 5.12 5.51 4.87 2.34 3.06 5.03 6.85
Price to Tangible Book Value (P/TBV)		 1.25 2.18 2.16 3.30 5.12 5.51 4.87 2.34 3.06 5.03 6.85
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 101.27 860.13 286.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.01 -1.00 -1.00 -1.00 -1.01 -1.00 -1.01 -1.01 -1.02 -1.01
Leverage Ratio		 1.07 1.06 1.04 1.05 1.06 1.06 1.05 1.04 1.05 1.06 1.05
Compound Leverage Factor		 0.94 0.95 0.86 0.87 0.89 0.93 0.93 0.88 0.91 0.95 0.95
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.23 19.40 37.06 47.76 66.96 54.67 50.43 33.98 40.99 51.35 79.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.23 19.50 37.08 30.24 26.35 19.93 20.99 28.87 26.51 19.85 22.61
Quick Ratio		 17.73 18.98 36.49 29.79 25.98 19.71 20.67 28.43 26.03 19.37 22.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -21 -29 -26 -24 -24 -20 -23 -26 -32 -42 -38
Operating Cash Flow to CapEx		 -4,826.70% -16,664.60% -9,628.96% -11,809.50% 0.00% -2,432.94% 0.00% -41,771.79% -33,120.00% -52,865.75% -16,362.69%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.73 0.44 2.18 -1.28 -3.66 -11 -6.67 -4.92 -4.69 -7.85 -6.36
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.73 5.67 1.29 -2.80 -4.39 -11 -8.85 -3.64 -1.03 3.10 0.31
Enterprise Value (EV)		 74 376 625 1,170 2,010 2,058 1,658 785 1,145 2,097 2,879
Market Capitalization		 364 694 1,158 1,682 2,503 2,528 2,095 1,379 1,709 2,627 3,379
Book Value per Share		 $4.58 $5.02 $6.11 $5.47 $5.21 $4.85 $4.51 $5.60 $5.30 $4.93 $4.60
Tangible Book Value per Share		 $4.58 $5.02 $6.11 $5.47 $5.21 $4.85 $4.51 $5.60 $5.30 $4.93 $4.60
Total Capital		 290 319 535 510 489 459 430 589 559 522 493
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -290 -318 -533 -512 -493 -470 -436 -594 -563 -530 -500
Capital Expenditures (CapEx)		 0.46 0.16 0.30 0.22 -0.31 1.11 0.00 0.08 0.11 0.07 0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.11 -8.17 -5.93 -9.49 -12 -19 -14 -12 -11 -14 -12
Debt-free Net Working Capital (DFNWC)		 282 310 527 502 480 452 422 582 552 516 487
Net Working Capital (NWC)		 282 310 527 502 480 452 422 582 552 516 487
Net Nonoperating Expense (NNE)		 5.10 6.44 4.20 4.82 5.83 7.78 8.63 6.29 7.87 11 11
Net Nonoperating Obligations (NNO)		 -290 -318 -533 -512 -493 -470 -436 -594 -563 -530 -500
Total Depreciation and Amortization (D&A)		 -1.88 -1.64 -2.63 -3.02 -2.64 -1.97 -1.37 -1.64 -1.49 -0.91 -0.42
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 63.46M 63.72M 87.57M 93.52M 93.81M 92.41M 95.13M 104.94M 105.49M 102.93M 107.12M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 63.46M 63.72M 87.57M 93.52M 93.81M 92.41M 95.13M 104.94M 105.49M 102.93M 107.12M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 63.46M 93.11M 93.40M 93.77M 94.69M 95.21M 105.20M 105.35M 105.87M 107.27M 107.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -24 -24 -27 -28 -32 -32 -30 -33 -39 -38
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Edgewise Therapeutics, Inc. (EWTX) — a concise, four-year look at quarterly statements (income, balance sheet, cash flow) to help informal investors gauge liquidity, profitability, and funding needs.

  • Liquidity remains robust: as of 2025-Q3, Cash & Equivalents = 46.0M and Short-Term Investments = 517.3M, totaling about 563M in liquid assets available to fund operating needs.
  • Equity financing has been a primary funding source: Q1 2025 net cash from continuing financing activities ≈ 241.1M and Q2 2025 ≈ 188.2M, supporting the company’s cash burn profile.
  • Selective investing activity generated net cash in 2025-Q3: Net Cash From Continuing Investing Activities ≈ 35.8M (largely from selling investments in excess of purchases), adding to liquidity.
  • Low leverage risk: near-term liabilities are modest (2025-Q3 Total Liabilities around 24.8M) relative to large asset base (~583M) and substantial equity base.
  • Total equity remains robust, reflecting ongoing financing and capital raised: 2025-Q1 ≈ 429.7M, 2025-Q2 ≈ 589.1M, with 2025-Q3 ≈ 558.6M in Total Equity.
  • No revenue yet in recent quarters (Total Revenue effectively 0.0), which is typical for a biotech company before a program reaches commercialization.
  • R&D and SG&A drive the burn: 2025-Q4 RD ≈ 43.6M and SGA ≈ 12.4M; 2025-Q3 RD ≈ 37.5M with SG&A ≈ 9.4M, indicating continued operating investment in pipeline and support functions.
  • A sizable investment portfolio exists (Short-Term Investments ≈ 517M in 2025-Q3), which provides liquidity but introduces market-risk considerations for non-operating gains/losses.
  • Persistent net losses: 2025-Q4 Net Income Attributable to Common Shareholders ≈ -49.96M; 2025-Q3 ≈ -40.67M; 2025-Q2 ≈ -31.50M; 2025-Q1 ≈ -40.80M, reflecting ongoing pre-revenue burn.
  • Operating cash flow is consistently negative: 2025-Q4 Net Cash From Continuing Operating Activities ≈ -38.59M; 2025-Q3 ≈ -34.78M; 2025-Q2 ≈ -32.58M; 2025-Q1 ≈ -37.87M, indicating cash burn before financing and investing activities.
  • Accumulated deficit shown on the balance sheet: Retained Earnings have been deeply negative (e.g., 2025-Q3 ≈ -496.16M; 2025-Q2 ≈ -455.49M; 2025-Q1 ≈ -419.37M), highlighting a long history of losses and ongoing reliance on external financing.
05/14/26 05:09 AM ETAI Generated. May Contain Errors.

Edgewise Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Edgewise Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Edgewise Therapeutics' net income appears to be on an upward trend, with a most recent value of -$167.80 million in 2025, rising from -$17.12 million in 2020. The previous period was -$133.81 million in 2024. See Edgewise Therapeutics' forecast for analyst expectations on what's next for the company.

Edgewise Therapeutics' total operating income in 2025 was -$191.41 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $191.41 million

Over the last 5 years, Edgewise Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Edgewise Therapeutics' total liabilities were at $30.35 million at the end of 2025, a 9.9% increase from 2024, and a 598.9% increase since 2020.

In the past 5 years, Edgewise Therapeutics' cash and equivalents has ranged from $15.57 million in 2021 to $104.92 million in 2020, and is currently $61.15 million as of their latest financial filing in 2025.

Over the last 5 years, Edgewise Therapeutics' book value per share changed from -45.22 in 2020 to 4.93 in 2025, a change of -110.9%.


Related Companies

Financial statements for NASDAQ:EWTX last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Is this AI lab Elon’s SpaceX lifeline?
Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...
Chaikin Analytics | Sponsoredtc pixel
The one number Musk can't hide in the S-1
When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
SpaceX IPO Warning: Before you buy any SpaceX shares, read this.
The SpaceX IPO is valued at $1.75 trillion - but buying shares directly may not be the strongest play availabl...
Weiss Ratings | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel